Some of the stuff that's kind of resonated with what Joanna is saying has been with investors in ETFs who are trying to figure out ways to enhance that yield. Have you seen any signs of stress in in your mind with regard to maybe possibilities for concern down the line because of deteriorating credit quality. Is is the economy flashing some signs that maybe things are slowing down a little bit.How exactly does the macro picture shape up given what we are seeing in terms of a tilt towards income strategies. ...

Core Insights - Alpine Income Property Trust (PINE) achieved a record $277.7 million in investment activity for 2025, alongside $82.8 million in property dispositions, indicating a proactive year in portfolio repositioning [1][7] - The company aims to enhance long-term cash flow generation by selling certain assets and reinvesting in higher-yielding structured investments and acquisitions [1] Investment Activity - In Q4, Alpine completed $142.1 million in acquisitions and structured investments with a high weighted average initial cash yield of 11.7%, including new first mortgage loan commitments [2] - The full-year investments yielded a 10.3% weighted average initial cash yield, reflecting strong cash return expectations [2] Portfolio Management - Disposition activities included sales of net-lease properties and structured investment participation interests, allowing for capital recycling into assets with better return profiles [3] - The company maintained a 99.4% occupancy rate with an 8.4-year weighted average remaining lease term as of December 31, 2025, supporting stable rent streams [3] Tenant Composition - Walmart has become the fourth-largest tenant, joining high-credit tenants like Lowe's and Dick's Sporting Goods, which increases exposure to strong, investment-grade rent sources [4] - Walgreens has slipped to the ninth position by annualized base rent, with five remaining leased properties in the portfolio [4] Strategic Outlook - Alpine's transaction activity in 2025 reflects a strategy focused on capital recycling and yield enhancement, positioning the REIT for resilient cash flow and income stability [5] - The company’s robust occupancy, long lease term profile, and increasing investment-grade tenant exposure indicate thoughtful portfolio management aimed at strengthening returns amid changing market conditions [5] Stock Performance - Shares of Alpine Income Property Trust have increased by 22.8% over the past three months, outperforming the industry, which saw a decline of 1.8% [6] - Analysts have revised consensus estimates for funds from operations (FFO) per share upward for both 2025 and 2026, suggesting year-over-year increases of 4.62% and 7.29%, respectively [6]

Financial Data and Key Metrics Changes - Total revenues for Q1 2025 reached $114.8 million, a year-over-year increase of $32.9 million, translating to approximately 40% growth [11][20] - Adjusted for voluntary product withdrawals, revenues would have been $118.6 million, representing approximately 45% year-over-year growth [11][20] - Adjusted net income grew by 87% year-over-year to $33.3 million, while adjusted EBITDA increased by 81% to $47.9 million [12][22] Business Line Data and Key Metrics Changes - The increase in total revenue is primarily attributed to higher sales of Ascentive, reflecting increased acceptance and utilization by physicians, payers, and patients [20] - Gross profit for Q1 2025 was $61.1 million, with a gross margin of 53.2%, up from 47.8% in Q1 2024, driven by a favorable mix of higher margin immunoglobulin sales [21] Market Data and Key Metrics Changes - The company has seen robust demand for its commercial products, particularly Ascentive and BIVIGAM, with new patient starts continuing to grow [13][14] - Cash on hand and accounts receivable grew to a combined $171 million at the end of Q1 2025, providing a strong buffer against market volatility [14][24] Company Strategy and Development Direction - The company is focused on advancing its R&D platform and optimizing production capabilities, particularly with the recent FDA approval of the yield enhancement production process, which is expected to increase bulk immunoglobulin output by 20% [8][12] - A stock repurchase program has been authorized, allowing the company to buy back up to $500 million of its common stock, reflecting confidence in its financial position and future growth [15][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve sustainable revenue and earnings growth, driven by a strong balance sheet and capital flexibility [14][26] - The company anticipates significant growth in cash flow and plans to utilize this for debt reduction, funding R&D, and stock repurchases [43][44] Other Important Information - The company has successfully navigated recent geopolitical and trade challenges due to its U.S.-based supply chain and domestic operations [7][8] - The FDA's approval of the yield enhancement process is seen as a pivotal achievement, validating the company's R&D efforts and enhancing its market position [9][10] Q&A Session Summary Question: Guidance increase and yield enhancement process - Management confirmed that three conformance lots were manufactured to secure FDA clearance, and they are conservatively excluding these from 2025 guidance [31][33] Question: Demand generation and backlog for Ascentive - Management indicated that operational expenses are expected to normalize, and demand indicators for all products are strong, supporting revenue growth [41][42] Question: Supply agreements and plasma collection - Management reported that nearly all new centers are contributing to plasma supply, exceeding initial forecasts and supporting increased guidance [49][51] Question: Health economic outcome data for Ascentive - Management is on track to publish health economic outcome data by year-end, which is expected to resonate with payers and support access to the drug [63][64] Question: Voluntary product withdrawals - Management clarified that the withdrawals were due to known adverse events and are considered a one-time occurrence, with no expected ongoing impacts [66][70] Question: Intellectual property extension - Management expressed confidence in extending the IP for Ascentive and highlighted the robust patent protection in place [72][75]